Risk factors
TELA Bio (TELA) risk factors
Item 1A of every TELA Bio, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors80 risks6 new1 dropped13 reworded
Nasdaq warned that TELA’s share price stayed below $1 for 30 business days, creating a delisting and capital-access risk.
Filed Mar 25, 2026 - FY2024 10-K risk factors75 risks
TELA Bio faces ongoing operating losses with an accumulated deficit of $358.7 million as of December 31, 2024. The company has $40.0 million in outstanding debt under its MidCap credit facility maturing in May 2027. Revenue remains highly concentrated in the OviTex product line and heavily dependent on exclusive manufacturer Aroa.
Filed Mar 21, 2025